Hologic, Inc. (HOLX)
| Market Cap | 16.04B |
| Revenue (ttm) | 5.32B |
| Net Income (ttm) | 1.91B |
| Shares Out | 258.47M |
| EPS (ttm) | 7.28 |
| PE Ratio | 8.65 |
| Forward PE | 13.95 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $62.99 |
| Previous Close | $62.61 |
| Change ($) | 0.38 |
| Change (%) | 0.61% |
| Day's Open | 62.67 |
| Day's Range | 62.04 - 63.19 |
| Day's Volume | 503,583 |
| 52-Week Range | 53.02 - 85.00 |
Hologic (HOLX) closed at $62.86 in the latest trading session, marking a +1.57% move from the prior day.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #acquisition--Hologic Completes Acquisition of Mobidiag
Hologic (HOLX) closed at $63.39 in the latest trading session, marking a +1.75% move from the prior day.
Hologic's (HOLX) Acessa procedure new coverage will further validate Laparoscopic Radiofrequency Ablation as a standard of care for uterine fibroids.
These businesses are running out of steam. Now may be the time to hit the sell button on their stocks.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Acessa--Cigna Updates Medical Policy to Cover Hologic's Acessa® Procedure, Expanding Access to Millions of Women Across the Country
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ACOG--New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #breastcancer--Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer
Getting beyond COVID-19 starts with going back to the base business.
Investors should hold off permanently rebranding diagnostics stocks as coronavirus stocks, experts say. There's a chance their future could be much brighter despite spreading vaccine use.
The stock price of Hologic (NASDAQ: HOLX), a medical devices company focused on women's health, has seen a large 12% drop in just five trading sessions. The decline was driven primarily due to the compa...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #presentation--Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic (HOLX) closed the most recent trading day at $65.92, moving +0.38% from the previous trading session.
Is (HOLX) Outperforming Other Medical Stocks This Year?
The three stocks listed below could be of interest to growth-oriented investors, as their price-earnings ratios are below 20 while their trailing 12-month earnings per share increased significantly over...
Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Hologic Inc (NASDAQ: HOLX) posted second-quarter results that trailed the consensus forecast; however, the company tried to provide some cushion with a better third-quarter fueled by COVID-19 test reven...
Hologic (HOLX) delivered earnings and revenue surprises of -1.15% and -0.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Hologic (NASDAQ:HOLX) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 354.39% year over year to $2.59, which missed the estimate o...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Second Quarter of Fiscal 2021
Hologic (HOLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.
Here we discuss three MedTech subsectors, which encourage us with their consistency through the pandemic year and are likely to have continued with their winning streak in Q121.
Hologic (HOLX) is likely to have gained during fiscal second-quarter 2021 on the back of robust performances of its business arms despite coronavirus-led economic doldrums.
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Hologic (HOLX) closed the most recent trading day at $76.68, moving +0.03% from the previous trading session.
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hologic's (HOLX) Mobidiag acquisition will generate long-term value by enabling the company to tap into the global acute care market.
Let's take a look at the three women healthcare MedTech stocks performing well lately.
Flush with cash from its Covid testing business, Hologic Inc. (NASDAQ:HOLX) continued its buying spree, laying out $795 million to add Mobidiag, the private Finnish-French molecular test maker, to the f...
Hologic Inc (NASDAQ: HOLX) has agreed to acquire Mobidiag Oy, a privately held, Europe-based provider of molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 mil...
Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million
Hologic (HOLX) possesses solid growth attributes, which could help it handily outperform the market.
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic to Announce Financial Results for the Second Quarter of Fiscal 2021 on Wednesday, April 28, 2021
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
In the latest trading session, Hologic (HOLX) closed at $73.87, marking a -0.44% move from the previous day.
Is (HOLX) Outperforming Other Medical Stocks This Year?
Grab these three top stocks - ABT, HOLX and BIO - that continue to show tremendous promise and stand to benefit from the historic stimulus package.
In the latest trading session, Hologic (HOLX) closed at $71.98, marking a -1.03% move from the previous day.
Investors remain optimistic about Hologic (HOLX) on its strong molecular diagnostic growth and robust international performance.
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fus... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 21, 1990 |
| CEO Stephen MacMillan | Employees 5,814 |
| Stock Exchange NASDAQ | Ticker Symbol HOLX |
Analyst Forecasts
According to 16 analysts, the average rating for Hologic stock is "Buy." The 12-month stock price forecast is 82.92, which is an increase of 31.64% from the latest price.